INT39000

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1983
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 24
Total Number 24
Disease Relevance 12.51
Pain Relevance 4.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
uterus 2
heart 2
TCL 1
arm 1
fingers 1
pr (Mus musculus)
Pain Link Frequency Relevance Heat
Oxycodone 89 100.00 Very High Very High Very High
narcan 71 100.00 Very High Very High Very High
Clonidine 8 98.72 Very High Very High Very High
Pain 39 96.76 Very High Very High Very High
Dismenorea 12 96.16 Very High Very High Very High
antagonist 6 91.24 High High
Onset of action 1 85.64 High High
carpal tunnel syndrome 8 84.40 Quite High
headache 3 76.00 Quite High
cva 11 75.00 Quite High
Disease Link Frequency Relevance Heat
Disease 123 99.98 Very High Very High Very High
Heart Rate Under Development 20 99.64 Very High Very High Very High
Arrhythmia Under Development 6 99.40 Very High Very High Very High
Increased Venous Pressure Under Development 5 99.18 Very High Very High Very High
Toxicity 32 98.62 Very High Very High Very High
Cancer 162 98.20 Very High Very High Very High
Fibrosarcoma 10 97.16 Very High Very High Very High
Pain 63 96.76 Very High Very High Very High
Dysmenorrhea 12 96.16 Very High Very High Very High
Diabetes Mellitus 210 94.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ECG intervals did not change with the exception of PR, which was prolonged by 0.9 mg clonidine daily (p less than 0.05).
Neg (not) Regulation (change) of PR associated with clonidine
1) Confidence 0.44 Published 1983 Journal Int J Clin Pharmacol Ther Toxicol Section Abstract Doc Link 6642791 Disease Relevance 0.60 Pain Relevance 0.68
Compared to the values obtained after placebo infusion, tiapamil significantly lowered systolic and diastolic blood pressure (respective pre- and posttiapamil values: 119.9 +/- 17.7 vs 142.1 +/- 25.5 mm Hg, p less than 0.01; and 72.0 +/- 9.1 vs 82.4 +/- 9.3 mm Hg, p less than 0.02); the drug exerted no significant effect on heart rate (63.9 +/- 13.3 vs 67.6 +/- 16.5 bpm, NS), PR interval (0.180 +/- 0.020 vs 0.177 +/- 0.017 sec NS), or QTc interval (404.4 +/- 16.5 vs 396.0 +/- 26.6 msec, NS).
Neg (no) Regulation (effect) of PR in heart
2) Confidence 0.44 Published 1985 Journal Am. Heart J. Section Abstract Doc Link 3885699 Disease Relevance 0.37 Pain Relevance 0.18
We show that PR intervals mature more quickly than heart rates do and are consistently and precisely regulated during development.
Regulation (regulated) of PR in heart
3) Confidence 0.33 Published 2010 Journal BMC Physiol Section Body Doc Link PMC2936334 Disease Relevance 0.70 Pain Relevance 0
While K5Cre*PR would not be a good choice if experimental design required gene manipulation in the entire basal cell population, that K5Cre*PR is more tightly regulated makes it an attractive construct for use in cancer models where targeting of sporadic mutations would more closely mimic the somatic mutations leading to the development of human cancer.
Regulation (regulated) of PR in basal cell associated with cancer
4) Confidence 0.13 Published 2010 Journal International Journal of Biological Sciences Section Body Doc Link PMC2815352 Disease Relevance 0.44 Pain Relevance 0.03
K5Cre*PR is tightly regulated with inducible and persistent Cre activity: The K5Cre*PR construct is analogous to K5CrePR1 except for a 16 amino acid deletion of the truncated progesterone receptor designed to reduce RU486-independent Cre recombinase activity 25.
Regulation (regulated) of PR
5) Confidence 0.13 Published 2010 Journal International Journal of Biological Sciences Section Body Doc Link PMC2815352 Disease Relevance 0.08 Pain Relevance 0
Five patients (8%) showed complete response (CR), 14 patients (58%) had partial response (PR), and 19 had good local control (CR 2, PR 17).
Regulation (control) of PR
6) Confidence 0.12 Published 1995 Journal J Surg Oncol Section Abstract Doc Link 7823574 Disease Relevance 0.64 Pain Relevance 0.07
Although care must be taken in extrapolating results in mice to humans, particularly under pathological conditions, our results suggest that it is safe to re-administer AAV vectors into the subretinal space to target PR and RPE cells without compromising the efficacy of the repeated gene transfers.



Regulation (target) of PR
7) Confidence 0.05 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2633462 Disease Relevance 0 Pain Relevance 0
Despite toxicity, the combination shows encouraging clinical activity with a disease control rate of 67% including one CR, three PR, and four SD.
Regulation (control) of PR associated with toxicity and disease
8) Confidence 0.04 Published 2010 Journal Clinical Epigenetics Section Body Doc Link PMC3020651 Disease Relevance 1.23 Pain Relevance 0
PR-immunoreactivity was observed only in fibroblasts of TCL and its expression decreased with age, while no immunolabeling was found in the synovial tissue.
Regulation (immunoreactivity) of PR in TCL
9) Confidence 0.03 Published 2008 Journal Cell Biol. Int. Section Abstract Doc Link 17951080 Disease Relevance 0.83 Pain Relevance 0.60
an objective response (3 CR and 3 PR, resp), confirming
Regulation (response) of PR
10) Confidence 0.02 Published 2006 Journal Sarcoma Section Body Doc Link PMC1510952 Disease Relevance 0.94 Pain Relevance 0
The study also assessed changes in the dose of oxycodone PR/naloxone PR during the study period.
Regulation (changes) of PR associated with oxycodone and narcan
11) Confidence 0.02 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 0.95 Pain Relevance 1.57
Labetalol had a significantly (P<0.05) better effect than esmolol in controlling PR at all points during the study.
Regulation (controlling) of PR
12) Confidence 0.02 Published 2010 Journal Saudi Journal of Anaesthesia Section Body Doc Link PMC2980662 Disease Relevance 0.08 Pain Relevance 0.13
It is clear from the Table 6 that all the areas do not have any correlation between PR and TPD values.
Regulation (values) of PR
13) Confidence 0.02 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772015 Disease Relevance 0.46 Pain Relevance 0
It is clear from the Table 4 that all the areas do not have any correlation between PR and TPD values.
Regulation (values) of PR
14) Confidence 0.02 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772015 Disease Relevance 0.77 Pain Relevance 0
It is clear from the Table 5 that all the areas do not have any correlation between PR and TPD values.
Regulation (values) of PR
15) Confidence 0.02 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772015 Disease Relevance 0.76 Pain Relevance 0
The findings show that changes in regulation of the concentrations of IGF-I-R, EGF-R, ER and PR in the uterus of women during menstrual cycles are related to the tissular localization of these receptors.
Regulation (regulation) of PR in uterus
16) Confidence 0.02 Published 1998 Journal Eur. J. Gynaecol. Oncol. Section Abstract Doc Link 9476071 Disease Relevance 0.38 Pain Relevance 0.38
We found that there is no correlation between TPD values measured using esthesiometer and shore values measured using shoremeter in the feet and no correlation between TPD and PR values measured using PPG in the feet.
Regulation (values) of PR
17) Confidence 0.02 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772015 Disease Relevance 0.55 Pain Relevance 0.08
We found that there is no correlation between TPD and shore value in the feet, similar to the observation by Dellon et al,[13] in fingers and no correlation between TPD and PR value in the feet.
Regulation (value) of PR in fingers
18) Confidence 0.02 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772015 Disease Relevance 0.45 Pain Relevance 0
Once-daily administration of pranidipine (1-2 mg) for 1-2 weeks decreased the 24-h average BP significantly from 167/92 mmHg to 150/83 mmHg without any change in pulse rate (PR) or the variabilities of BP and PR.
Regulation (change) of PR
19) Confidence 0.02 Published 1995 Journal Int J Clin Pharmacol Ther Section Abstract Doc Link 7655766 Disease Relevance 0.21 Pain Relevance 0.14
Hemodynamic parameters related to vasodilation and reflex tachycardia, such as maximum changes in diastolic BP, PR, CI, and TPR, showed significant dose-dependent changes.
Regulation (changes) of PR associated with heart rate under development and increased venous pressure under development
20) Confidence 0.02 Published 2000 Journal J Clin Pharmacol Section Abstract Doc Link 10883417 Disease Relevance 0.44 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox